MOLN Molecular Partners AG ADRs

Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland. This is an ADR of a company whose stock trades outside of the U.S. as the symbol SE:MOLN.

$6.97  +0.11 (1.60%)
As of 05/26/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Switzerland
Country of incorporation:  
IPO date:  11/05/2014
Outstanding shares:  32,502,323
Average volume:  49,123
Market cap:   $222,965,936
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      BRJLB32
Valuation   (See tab for details)
PE ratio:   2.12
PB ratio:   0.85
PS ratio:   1.20
Return on equity:   40.04%
Net income %:   58.54%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy